First, FGF-21 can mitigate metabolic disorders without inducing hypoglycemia or mitogenesis (Kharitonenkov et al., 2005), which shows the future significance of FGF-21-based therapies for metabolic diseases. This evidence concerns the gene FGF21 and Other metabolic disease.